Rxcurve
Medicare Part B payment limits Effective October 1 – December 31, 2026 Posted by CMS September 17, 2026
HCPCS J0688 · per 500 MG

Inj cefazolin sodium, hikma

Products billed under this code include Cefazolin Sodium.

Payment limit per 500 MG, by effective quarter, 1Q24 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.

Products billed under J0688

From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.

ProductLabelerNDCUnits / pkgLimit / pkg
Cefazolin Sodium Hikma Pharmaceuticals USA Inc. 00143-9139-25 100 $82.90
Cefazolin Sodium Hikma Pharmaceuticals USA Inc. 00143-9140-25 150 $124.35

Every quarter

QuarterPayment limitChangeBilling unitDescriptionSource file
4Q26 $0.829 −$0.018 500 MG Inj cefazolin sodium, hikma v1, posted September 17, 2026
3Q26 $0.847 −$0.003 500 MG Inj cefazolin sodium, hikma v1, posted September 15, 2026
2Q26 $0.85 −$0.025 500 MG Inj cefazolin sodium, hikma v1, posted September 15, 2026
1Q26 $0.875 −$0.051 500 MG Inj cefazolin sodium, hikma v1, posted September 15, 2026
4Q25 $0.926 +$0.012 500 MG Inj cefazolin sodium, hikma v1, posted September 8, 2026
3Q25 $0.914 −$0.068 500 MG Inj cefazolin sodium, hikma v1, posted March 10, 2026
2Q25 $0.982 −$0.021 500 MG Inj cefazolin sodium, hikma v1, posted March 10, 2026
1Q25 $1.003 +$0.019 500 MG Inj cefazolin sodium, hikma v1, posted December 19, 2025
4Q24 $0.984 −$0.077 500 MG Inj cefazolin sodium, hikma v1, posted June 11, 2025
3Q24 $1.061 −$0.023 500 MG Inj cefazolin sodium, hikma v1, posted June 11, 2025
2Q24 $1.084 +$0.042 500 MG Inj cefazolin sodium, hikma v1, posted March 11, 2025
1Q24 $1.042 – 500 MG Inj cefazolin sodium, hikma v1, posted December 19, 2024

“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.

CMS source files